Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer

计划入组 30 人 · 首次发布于 2017 年 6 月 23 日

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

计划入组 25 人 · 首次发布于 2026 年 4 月 29 日

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

计划入组 40 人 · 首次发布于 2022 年 11 月 23 日

Sofusa anti-PD-1

89Zr-anti-PD-1

anti-PD-1-hIL2 (cancer)

PD-RX Pharmaceuticals, Inc.

United States

NHI-1

United States

Novel Anti-Infective Technologies, LLC

Anti-PD-1 Immunotherapy Shows Promise for Drug-Free HIV Control in Phase 1 Trial

Anti-PD-1 Immunotherapy Shows Superior Outcomes in Gastric Cancer Patients with Chronic Hepatitis B

FDA Approves Genentech's Tecentriq Hybreza, First Subcutaneous Anti-PD-(L)1 Immunotherapy